FIG
PMVP icon

Freed Investment Group’s PMV Pharmaceuticals PMVP Stock Holding History

Freed Investment Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$741K Buy
+24,880
New +$794K 0.56% 10

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Freed Investment Group's PMVP Position: Q3 2021 in Review

Freed Investment Group opened a new position in PMV Pharmaceuticals (PMVP) in Q3 2021: 24,880 shares worth $741K. The stake represents 0.56% of the portfolio and ranks #10 among its holdings.

92 funds tracked by Wall St. Rank hold PMVP as of Q3 2021.

  • Freed Investment Group held 24,880 shares of PMV Pharmaceuticals worth $741K as of Q3 2021.
  • PMV Pharmaceuticals was a new Freed Investment Group position in Q3 2021.
  • PMV Pharmaceuticals made up 0.56% of Freed Investment Group's portfolio in Q3 2021, its #10 holding.
  • 92 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2021.

Based on Freed Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.